Type 2 diabetes is not always a disease of excess weight. About one in five diabetics worldwide remain lean, yet their bodies still struggle to process blood sugar effectively. A new Brazilian study suggests that fish oil may hold unexpected promise for this overlooked patient group by dampening the inflammation that drives insulin resistance even without obesity.
Researchers at Brazilian institutions gave fish oil supplements to non-obese rats engineered to develop diabetes naturally. After eight weeks of treatment, the animals showed lower insulin resistance, improved blood sugar control, reduced inflammatory markers, and better cholesterol and triglyceride levels. The mechanism appeared to work through immune cells called lymphocytes, which shifted from a pro-inflammatory state toward a protective anti-inflammatory profile.
The study, published in Nutrients and funded by the São Paulo Research Foundation, used Goto-Kakizaki rats, a well-established animal model that mirrors type 2 diabetes in humans without obesity. The fish oil dose contained 540 mg per gram of EPA and 100 mg per gram of DHA, administered three times weekly.
Inflammation Without Obesity
Obesity remains a major risk factor for type 2 diabetes, but it is far from the whole story. In lean people with diabetes, the biological roots of insulin resistance may operate through different pathways than weight-driven disease. Understanding how omega-3 fatty acids affect these non-obesity forms of diabetes has received little scientific attention until now.
Most obese people with diabetes experience chronic low-level inflammation driven by their enlarged adipose tissue, which releases pro-inflammatory signals that interfere with insulin signaling. In non-obese diabetes, that tissue amplification does not occur, yet systemic inflammation persists through other mechanisms. The Brazilian team found that early immune dysfunction appears in young non-obese diabetic rats, with changes in key regulatory immune cells visible even before obvious symptoms emerge.
Rui Curi, coordinator of the study and director of the Butantan Institute's Education Center, noted that genetic factors may play a central role in lean-onset diabetes. His team has also explored whether delayed intestinal transit might contribute to insulin resistance in people without obesity, suggesting that multiple biological pathways deserve investigation.
When inflammatory signals remain elevated, they interfere with how cells respond to insulin. The new work adds to a growing scientific view that type 2 diabetes is shaped not just by metabolic dysfunction but by the immune system itself.
How Fish Oil Shifted the Balance
In the treatment group, fish oil supplementation reversed the pro-inflammatory immune profile. Levels of Th1 and Th17 cells, lymphocyte subtypes that drive harmful inflammation, declined. Meanwhile, regulatory T-cells, which inhibit pro-inflammatory activity, increased. This immune rebalancing appeared to trigger the improvement in insulin resistance observed across multiple markers.
The shift mattered because insulin resistance is not purely a problem of sugar metabolism. It is deeply rooted in inflammatory activity. By changing the inflammatory environment, the omega-3 fatty acids appeared to improve blood sugar regulation without relying on changes in fat metabolism alone.
These findings have drawn attention from human researchers. A 2025 double-blind randomized controlled trial in healthy middle-aged and older adults found that fish oil supplementation over 12 weeks produced dose-related increases in serum EPA and DHA levels. Fasting insulin and the HOMA-IR index, a standard marker of insulin resistance, both declined in the treatment groups. A separate 2024 analysis of 161 type 2 diabetes patients reported a dose-related association between omega-3 levels and long-term blood sugar control, though researchers noted the evidence remains debated.
Still, animal studies reveal biological mechanisms but do not prove human benefit. The Brazilian team stressed that clinical trials are necessary before omega-3 therapy can be recommended for lean patients with type 2 diabetes. The ideal dose and specific type of omega-3 fatty acid for human treatment remain unknown.
The work reveals that body weight may not be the primary driver of insulin resistance in all people with type 2 diabetes. Inflammation can operate independently of obesity, and omega-3 fatty acids appear to influence that hidden process in measurable ways. For a patient population long overshadowed by obesity-focused research, that clue opens a new avenue for understanding and potentially treating their disease.
Author Jessica Williams: "This study matters because lean diabetics have been largely ignored in research, yet they face real medical struggles that deserve targeted solutions."
Comments